you are viewing a single comment's thread.
WIDER LOSSInterMune loss from continuing operations widened to $50.9 million, or 78 cents per share, in the second quarter from $41.3 million, or 70 cents per share, a year earlier.Including the one-time payment from the sale of Actimmune, the company posted a net profit of $490,000, or 1 cent per share.Esbriet, which was rejected by the U.S. Food and Drug Administration in May 2010, is currently being studied in a late-stage trial.InterMune expects to complete enrollment by the year end. William Blair analyst Xu expects data from the trial by 2014.
Excellent, this is what I was thinking. I knew it had been rejected in 2010, just wasn't sure if it was up again for enrollment this year. TY